P-099 Current Smoking Status Is a Risk Factor For Loss of Remission in Crohnʼs Disease Patients Treated with Certolizumab Pegol

Gender is a risk factor in patients with gastroesophageal reflux disease

Background: Prevalence of gastroesophageal reflux disease (GERD) has increased in the last decades, and it is now one of the most common chronic and recurrent diseases. The present study aimed at determining the frequency of gender (sex) and age in Iranian patients with GERD symptoms.    Methods: In this study, 803 patients aged 11 to 84 years, with erosive and nonerosive gastroesoph...

Certolizumab pegol in the treatment of Crohn's disease.

INTRODUCTION The introduction of antibodies directed against tumour necrosis factor (anti-TNF) has dramatically changed the concept of treating patients with Crohn's disease (CD). Unfortunately, the long-term efficacy of anti-TNF agents may be hampered by immunogenicity. The availability of more anti-TNF agents in the therapeutic armamentarium would therefore be of great benefit in patients loo...

Certolizumab pegol for the treatment of Crohn's disease.

In this article we provide a contemporary overview of available clinical data on certolizumab pegol, a pegylated anti-tumor necrosis factor (TNF) alpha agent that comprises a uniquely small protein, and its emerging role as a therapy for Crohn's disease (CD). The results from a comprehensive clinical trial program suggest that certolizumab pegol offers rapid and sustained remission of moderate ...

Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease

BACKGROUND Therapeutic drug monitoring may optimize therapy for Crohn's disease (CD). AIM To use a population pharmacokinetic model that accounts for the time-varying nature of covariates to simulate certolizumab pegol (CZP) concentrations to evaluate the exposure-response relationship for CZP in Crohn's disease. METHODS Adults (N = 2157) with Crohn's disease were treated with CZP in nine c...

Human T Lymphotropic Virus Type I (HTLV-I) is a Risk Factor for Coronary Artery Disease